磷酸奥司他韦联合重组人干扰素α-2b治疗儿童手足口病的疗效观察

Efficacy of oseltamivir phosphate combined with recombinant human interferon α-2b in the treatment of hand-foot-mouth disease in children

目的:观察磷酸奥司他韦联合重组人干扰素α-2b治疗儿童手足口病的疗效。方法:选取手足口病患儿84例,按随机数字表法分为两组,每组各42例。对照组采用重组人干扰素α-2b治疗,研究组在对照组基础上联用磷酸奥司他韦。比较两组疗效、症状缓解及住院时间。结果:研究组治疗总有效率高于对照组,咳嗽咳痰、体温、咽部红肿、肺罗音消失和住院时间均短于对照组,差异有统计学意义(P<0.05)。结论:磷酸奥司他韦联合重组人干扰素α-2b治疗可提高儿童手足口病的疗效,缩短症状缓解与住院时间,促进康复。

Objective: To observe the efficacy of oseltamivir phosphate combined with recombinant human interferon α-2 b in the treatment of hand-foot-mouth disease in children. Methods: 84 children with HFMD were randomized into two groups, with 42 cases in each group. The control group were treated with recombinant human interferon α-2 b, while the study group were treated with oseltamivir phosphate on the basis of the control group. The two groups were compared in terms of symptom relief and hospitalization time. Results: The total effective rate of the study group was higher than that of the control group, cough and expectoration, body temperature, pharyngeal redness and swelling, disappearance of lung rales and hospitalization time were shorter than those of the control group, and there were statistical differences(P<0.05). Conclusion: Oseltamivir phosphate combined with recombinant human interferon α-2 b can improve the curative effect of hand-foot-mouth disease in children, shorten the symptom relief and hospitalization time, and promote the recovery.